Does NMN Lower Blood Sugar? Contradicted Evidence, 8 Trials Reviewed

Three meta-analyses, one answer, and a single clamp study doing all the work for the marketing.

Presented By Our Partners

No. In a 2024 meta-analysis of 8 randomized trials with 342 participants, NMN at 250 to 2,000 mg per day for 14 days to 12 weeks had no significant effect on fasting glucose, fasting insulin, HbA1c, HOMA-IR or lipid profile (PMID 39531138). Two further pooled analyses reached the same conclusion: across 12 RCTs (n=513), blood NAD rose while fasting glucose and lipids did not differ from control (PMID 39116016), and across 15 RCTs, fasting glucose, HbA1c and lipids were unchanged with only a non-significant downward trend in HOMA-IR (PMID 42514320). Healthcare Discovery grades the blood sugar claim as contradicted, the only grade in the NMN set where controlled trials show no effect in the direction benefit is sold, and scores it 64 out of 100 on the HYPE Index, a Significant Evidence Gap. The score is high not because the evidence is thin but because the claim is still sold after three null meta-analyses, and the E axis of the HYPE Index weighs that failure to update heavily.

What the trials found

Where the claim came from

The entire blood sugar story traces to one trial. In 2021, a 10-week randomized study of overweight or obese postmenopausal women with prediabetes found that NMN increased insulin-stimulated glucose disposal measured by hyperinsulinemic-euglycemic clamp, the gold-standard method, and increased muscle insulin signaling through AKT and mTOR phosphorylation, while placebo produced no change (PMID 33888596). The muscle-specific insulin sensitivity improvement was about 25 percent. It was a real result in a well-designed study. It was also a result in a narrow population: 25 women, 13 of them on 250 mg per day, and the full report shows that fasting plasma glucose, insulin, liver fat, body composition and blood pressure did not change in either group. The hypothesis tested was that NMN improves muscle insulin sensitivity in prediabetic postmenopausal women. The broader blood sugar claim stretches that result to everyone. That distance is the H5 criterion of the HYPE Index, and it is where this claim loses most of its points.

Every trial since has failed to extend the finding. The 80-person dose-ranging study found no HOMA-IR change at 300 to 900 mg per day over 60 days (PMID 36482258). The MIB-626 trial at 2,000 mg per day produced weight loss and lower cholesterol but no change in insulin sensitivity (PMID 36740954). The 24-week trial in older diabetic men measured grip strength and walking speed rather than glucose and was null on both (PMID 36443648). When the trials were pooled, three separate research groups found nothing on glucose, insulin, HbA1c or HOMA-IR. Two of the null trials had company-affiliated authors, the 80-person trial co-sponsored by the NMN makers ABA Chemicals and Abinopharm (PMID 36482258) and the MIB-626 trial with an author from its developer, Metro International Biotech (PMID 36740954), so the null glycemic results do not come only from skeptics.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

What we do not know

Whether people with established type 2 diabetes respond differently over longer than 12 weeks, because the pooled trials enrolled mainly non-diabetic adults and the longest ran 24 weeks. Whether the muscle-specific clamp result in prediabetic women would replicate, because no second clamp study has been published. Whether the subgroup hint from the 9-trial analysis, that smaller doses had a larger HOMA-IR effect, is anything more than noise (PMID 39185644). And whether NMN interacts with glucose-lowering drugs, which Healthcare Discovery lists as a theoretical interaction because no trial enrolled medicated diabetics and no hypoglycemia has been reported. For ingredients where the glycemic evidence is stronger, see Healthcare Discovery’s Does Berberine Lower Blood Sugar and Curcumin for Blood Sugar.

Doses used in studies

These are doses reported by the named sources, not recommendations.

The complete grading of all ten NMN claims is in Healthcare Discovery’s NMN evidence review. Method at HYPE Index methodology.

Compiled by Healthcare Discovery from the cited PubMed studies. Every citation, author affiliation and trial sponsor named on this page was checked against PubMed on October 27, 2026. How claims are scored: HYPE Index methodology.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.

Keep Reading on Healthcare Discovery

• myDNAge Epigenetic Clock: The Original Horvath Clock Made Consumer-Accessible
• Polar Vantage V3 Review: Recovery, Training Load, and VO2 Max
• The Daily Rounds: Longevity & Health Care Brief | April 19, 2026